Format

Send to

Choose Destination
Elife. 2017 Sep 28;6. pii: e27873. doi: 10.7554/eLife.27873.

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.

Author information

1
Department of Pediatrics, Stanford University, Stanford, United States.
2
Department of Medicine, Division of Hematology, Stanford University, Stanford, United States.
3
Department of Medicine, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, United States.
4
Department of Medicine, Cancer Institute, Stanford University, Stanford, United States.
#
Contributed equally

Abstract

Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.

KEYWORDS:

CRISPR/Cas9; developmental biology; evolutionary biology; gene editing; genomics; hematopoietic stem cells; human; mouse; multiplex; stem cells

PMID:
28956530
PMCID:
PMC5656432
DOI:
10.7554/eLife.27873
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for eLife Sciences Publications, Ltd Icon for PubMed Central
Loading ...
Support Center